Tens Unit Articles & Analysis
12 news found
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania ...
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania ...
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania ...
Substance use is an escalating crisis in the United States, with opioid-related drug overdose deaths rising above 100,000 in 2021.1 The standard of care for treating opioid use disorder (OUD) is medication for opioid use disorder (MOUD), including opioid receptor agonists and antagonists. ...
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania ...
(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of ...
The opportunity for our business is to scale into the total serviceable market of more than ten million tests per year in the United States alone through organic growth, partnership, and joint ventures. ...
The primary efficacy endpoint was the Montgomery–Asberg Depression Scale (MADRS) score. The trial was conducted at ten centers in the United States from May 2018 to August 2019. "We look forward to seeing esmethadone potentially helping millions of depressed patients with inadequate response to antidepressants if these efficacy and safety results are ...
” About the Trial The trial will enroll ten patients in the United States and Canada. The primary objective of the Ph1 study is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. ...
“This is an important step to advance treatment using a novel strategy for a disease that does not yet have a cure and could change lives for many patients.” The trial will enroll ten patients in the United States and Canada, with the Canadian trial site at University Health Network, Canada’s largest research and teaching hospital network, ...
Atsushi Horiba, President & CEO of HORIBA, Ltd., signed the Letter of Commitment of the United Nations Global Compact (UNGC) and submitted it to the United Nations through the office of Global Compact Japan Network. ...
(Nasdaq: HSIC), the largest distributor of health care products and services to office-based practitioners, announced today that Healthy Lifestyles, Healthy Communities will provide free medical and dental services to more than 5,000 children and their caregivers in five cities throughout the United States this summer and fall. In addition, as part of this initiative, Henry ...